Researchers have developed a synthetic version of a cardiac stem cell that could offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies.
Stem cell therapies aid damaged tissue in repairing itself by secreting "paracrine factors," including proteins and genetic materials.
While stem cell therapies can be effective, they are also associated with some risks of both tumour growth and immune rejection.
Also, the cells themselves are very fragile, requiring careful storage and a multi-step process of typing and characterisation before they can be used.
"The synthetic cells operate much the same way a deactivated vaccine works," said Ke Cheng, Associate Professor at North Carolina State University in the US.
"Their membranes allow them to bypass the immune response, bind to cardiac tissue, release the growth factors and generate repair, but they cannot amplify by themselves. So you get the benefits of stem cell therapy without risks," Cheng explained.
In this study, reported in the journal Nature Communications, the researchers created the synthetic version of a cardiac stem cell that could be used in off-the-shelf applications.
When tested in vitro, it was found to promote the growth of cardiac muscle cells.
The synthetic stem cells are much more durable than human stem cells, and could tolerate harsh freezing and thawing.
They also do not have to be derived from the patient's own cells and the manufacturing process can be used with any type of stem cell, said the study.
"We are hoping that this may be a first step toward a truly off-the-shelf stem cell product that would enable people to receive beneficial stem cell therapies when they're needed, without costly delays," Cheng said.
--IANS
gb/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
